Tempus AI, Inc.'s unique data assets and AI-driven oncology solutions make it a promising buy. Click to read more on why the ...

The increasing incidence of infectious and chronic illnesses is boosting the need for early and precise diagnosis, with AI playing a crucial role by ...

Artificial intelligence allows us to examine that data to identify certain types of heart disease sooner and get personalized ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the William Blair 45th Annual Growth Stock Conference ...

Tempus AI, Inc. is revolutionizing healthcare genomics with AI and data partnerships. Click here to read an analysis on TEM ...

Tempus' FDA-approved xT CDx test is being used as an investigational assay in Verastem's global Phase 3 RAMP-301 clinical trial.

Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.

Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised ...

The Chicago-based Tempus spinout called the financing round a major milestone as it expands its AI-enabled platform.

In the assessment of 12-month price targets, analysts unveil insights for Tempus AI, presenting an average target of $64.09, ...

"By combining internal, pre-clinical experimental data, with real-world data from Tempus on its AI-powered platform, we can profoundly deepen our understanding of cancer biology and accelerate our ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...